IBI-80090

In November, 2012 IBI received FDA approval of its Orphan Drug Designation for IBI-80090 (mephalan for intraocular injection) for the treatment of retinoblastoma.  IBI will be collaborating with Memorial Sloan Kettering Cancer Center on this project.

Categories

Disclaimer

My Canadian Pharmacy is an informative service. All the information should not be used in the purposes to establish a diagnosis and prescribe a treatment plan. Our company is a vendor, not a drug manufacturer. We cooperate with drug manufacturers who distribute their products to us. We have no relation with Icon Bioscience and Verisome. They move to another domain. We bear no responsibility for any damage brought to your health. All the questions related to the drug quality should be addressed to the drug manufacturer directly.